Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).

Michele Iuliani Sonia SimonettiLeonardo CristofaniSilvia CavaliereAlessio CortelliniMarco RussanoBruno VincenziGiuseppe ToniniDaniele SantiniFrancesco Pantano

Published in: Journal for immunotherapy of cancer (2024)

These results highlight the prognostic and predictive value of RANKL specifically in patients with high PDL1 expression.

Keyphrases

nuclear factor
advanced non small cell lung cancer
toll like receptor
epidermal growth factor receptor
poor prognosis
binding protein
tyrosine kinase
small cell lung cancer